Recent news highlights Henry Schein's Q3 2026 financial results showing earnings growth, stable revenues, and an increased adjusted income outlook for fiscal 2026. The company reported earnings exceeding prior expectations and raised its EPS view for 2026. Sales growth was supported across dental merchandise, equipment, medical products, specialty products, and technology solutions.

• Henry Schein reported Q3 2026 financial results with earnings growth and raised fiscal 2026 guidance for adjusted income [N1].
• Q3 2026 earnings exceeded prior expectations with revenues matching prior levels and an increased EPS outlook for 2026 [N3][N5].
• Sales climbed in Q3 2026 across dental merchandise, dental equipment, medical products, specialty products, and technology segments [N1][N4].
• The company continues to execute its acquisition strategy focused on high growth, high margin businesses aligned with its BOLD+1 strategy [N1].
• Liquidity remains solid with a current ratio of 1.33 as of September 26, 2026, supporting operational and capital needs [S2].

Henry Schein's diversified business model across distribution, specialty products, and technology segments provides multiple revenue streams. The company has demonstrated steady sales growth and profitability, supported by acquisitions aligned with its strategic BOLD+1 plan. Recent financial results indicate operational strength with improved earnings and raised income outlook. Its investments in technology and e-commerce platforms position it to capitalize on digital transformation trends in healthcare. The company's liquidity and capital resources support continued execution of growth and efficiency initiatives [S1][N1][N4].

Risks include exposure to regulatory and tax changes, including global minimum tax rules that may affect effective tax rates and cash tax liabilities. The company faces operational risks from restructuring activities and integration of acquisitions, which may incur costs and disrupt operations. Fluctuations in working capital due to seasonal inventory and sales patterns can impact liquidity. Competitive pressures in healthcare distribution and technology markets may affect margins and growth. Economic or market downturns could reduce demand for the company's products and services [S1].

Henry Schein's moat is supported by its broad and diversified product and service portfolio across dental and medical markets, extensive distribution network, and integrated technology solutions. Its scale and global footprint provide competitive advantages in sourcing, logistics, and customer relationships. The company's focus on high-margin specialty products and proprietary technology platforms further differentiates it from competitors. Ongoing restructuring and strategic acquisitions aim to strengthen operational efficiency and expand market presence, reinforcing its competitive position [S1].

• Regulatory and Tax Risks: Changes in laws, regulations, and tax provisions, including global minimum tax rules, may adversely impact effective tax rates and cash tax liabilities.
• Restructuring and Integration Risks: Ongoing restructuring plans and acquisition integrations may result in costs, operational disruptions, and uncertainties in achieving efficiencies.
• Working Capital and Liquidity Risks: Seasonal fluctuations in inventory purchase patterns and sales demand can affect working capital requirements and liquidity.
• Competitive and Market Risks: Intense competition in healthcare distribution and technology sectors may pressure margins and growth prospects.

• Henry Schein Inc operates through three reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology [S1].
• Global Distribution and Value-Added Services segment includes dental merchandise, dental equipment, and value-added services such as financial services and consulting [S1].
• Global Specialty Products segment involves manufacturing, marketing, and sales of dental implant and biomaterial products, endodontic, orthodontic, orthopedic products, and other healthcare-related products and services [S1].
• Global Technology segment develops and distributes practice management software, e-services, and other technology-enabled products for healthcare providers [S1].
• For the fiscal year ended December 27, 2025, Henry Schein reported net sales of $13.184 billion, a 4.0% increase from the prior year, driven by internal growth, acquisitions, and foreign exchange impacts [S1].
• Gross profit for 2025 was $4.105 billion with a gross margin of 31.1%, slightly down from 31.7% in 2024, reflecting product mix and promotional programs [S1].
• Operating expenses increased slightly to $3.452 billion in 2025, including restructuring and related costs of $105 million associated with a 2024 restructuring plan expected to complete by end of 2027 [S1].
• Net income attributable to Henry Schein was $398 million for 2025 [S1].
• Liquidity as of September 26, 2026, includes current assets of $4.776 billion and current liabilities of $3.598 billion, yielding a current ratio of 1.33 and a cash ratio of 0.02 [S2].
• Net income for the quarter ended September 26, 2026, was $119 million with basic EPS of $1.07 and diluted EPS of $1.06 [S2].
• Recent Q3 2026 financial results showed earnings growth and an increase in adjusted income outlook for fiscal 2026 [N1][N4].
• The company reported Q3 earnings that exceeded prior expectations with revenues matching prior levels and raised its EPS view for 2026 [N3][N5].
• Sales growth in Q3 2026 was supported by increases in dental merchandise, dental equipment, medical products, specialty products, and technology solutions [N1][N4].
• Henry Schein's acquisition strategy focuses on high growth, high margin businesses aligned with its BOLD+1 strategy to expand customer base, geographic footprint, and access to new products and technologies [S1].
• The company finances operations primarily through cash generated from operations, revolving credit facilities, and debt placements, maintaining sufficient liquidity for foreseeable capital needs [S1].
• Restructuring plans initiated in 2022 and 2024 aim to integrate acquisitions, right-size operations, and increase efficiencies, with related charges recorded in recent years [S1].
• The company faces risks related to regulatory changes, tax reforms including global minimum tax rules, and fluctuations in working capital due to seasonal inventory and sales patterns [S1].